- Home
- SNTI vs ATIF Comparison
SNTI vs ATIF Comparison
Compare SNTI & ATIF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNTI
- ATIF
- Stock Information
- Founded
- SNTI 2016
- ATIF 2015
- Country
- SNTI United States
- ATIF United States
- Employees
- SNTI N/A
- ATIF N/A
- Industry
- SNTI Biotechnology: Pharmaceutical Preparations
- ATIF Professional Services
- Sector
- SNTI Health Care
- ATIF Consumer Discretionary
- Exchange
- SNTI Nasdaq
- ATIF Nasdaq
- Market Cap
- SNTI 10.4M
- ATIF 8.9M
- IPO Year
- SNTI N/A
- ATIF 2019
- Fundamental
- Price
- SNTI $4.41
- ATIF $0.64
- Analyst Decision
- SNTI Strong Buy
- ATIF
- Analyst Count
- SNTI 1
- ATIF 0
- Target Price
- SNTI $12.00
- ATIF N/A
- AVG Volume (30 Days)
- SNTI 7.0M
- ATIF 366.1K
- Earning Date
- SNTI 11-14-2024
- ATIF 12-31-2024
- Dividend Yield
- SNTI N/A
- ATIF N/A
- EPS Growth
- SNTI N/A
- ATIF N/A
- EPS
- SNTI N/A
- ATIF N/A
- Revenue
- SNTI N/A
- ATIF $620,000.00
- Revenue This Year
- SNTI $254.47
- ATIF N/A
- Revenue Next Year
- SNTI $169.66
- ATIF N/A
- P/E Ratio
- SNTI N/A
- ATIF N/A
- Revenue Growth
- SNTI N/A
- ATIF N/A
- 52 Week Low
- SNTI $1.52
- ATIF $0.58
- 52 Week High
- SNTI $16.94
- ATIF $1.50
- Technical
- Relative Strength Index (RSI)
- SNTI 52.77
- ATIF 43.99
- Support Level
- SNTI $4.62
- ATIF $0.70
- Resistance Level
- SNTI $5.96
- ATIF $1.25
- Average True Range (ATR)
- SNTI 1.63
- ATIF 0.10
- MACD
- SNTI -0.14
- ATIF 0.01
- Stochastic Oscillator
- SNTI 18.48
- ATIF 6.39
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with their gene circuit platform technologies to fight challenging diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
About ATIF ATIF Holdings Limited
ATIF Holdings Ltd is a consulting company. It provides financial and advisory services to small and medium-sized enterprises and also to individual customers and families. The firm also offers Pre-IPO's, and Post-IPO's services. It operates in one operating segment which is the consulting service business. It generates the majority of its revenue from the USA.